The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Intravitreal CendR peptides target laser-induced choroidal neovascularization sites in mice
Abstract
Choroidal neovascularization (CNV) is a common ocular pathology that may be associated in a variety of eye diseases. Although intravitreal injection treatment of anti-vascular endothelial growth factor (anti-VEGF) drugs shows significant clinical benefits in CNV treatment, the limitations of the current therapy need to be addressed. The aim of our study was to investigate the potential utility of three C-end Rule (CendR) peptides (RPARPAR, PL3, iRGD) for CNV targeting and to evaluate the efficacy of peptides for treating experimental CNV in mice. We observed that the CendR peptides localize to the CNV lesion sites after intravitreal injection and were mainly found in the outer nuclear cell layer (ONL) of the mouse retina. Interestingly, experimental therapy with tenascin-C (TNC-C) and neuropilin-1 (NRP-1)-targeting PL3 peptide, reduced angiogenesis and decreased vascular leakage. The results suggest that PL3 and potentially other CendR peptides could serve as affinity targeting ligands and therapeutics for ocular diseases that involve pathological CNV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the eye, iRGD, RPARPAR, and PL3 traverse from choroid through the retinal pigment epithelium to the outer nuclear layer and cut leakage by about fifty percent in a laser induced choroidal neovascularization model [90].”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [90]
Citations
Cites
Puranen, J., Koponen, S., Nieminen, T., Kanerva, I., Kokki, E., Toivanen, P., Urtti, A., Ylä-Herttuala, S., & Ruponen, M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109237 · Cited by 9
Self-citation
Research works printed but not linked: 36
- Li, 2012, Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery, J. Transl. Med., 10, S1, 10.1186/1479-5876-10-S1-S1 · DOI
- Lu, 2017, Vascular-homing peptides for cancer therapy, Biomed. Pharmacother., 92, 187, 10.1016/j.biopha.2017.05.054 · DOI
- Ruoslahti, 2000, Targeting tumor vasculature with homing peptides from phage display, Semin. Cancer Biol., 10, 435, 10.1006/scbi.2000.0334 · DOI · Paper page
- Teesalu, 2009, C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration, Proc. Natl. Acad. Sci. U. S. A., 106, 16157, 10.1073/pnas.0908201106 · DOI · Paper page
- Pang, 2014, A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity, J. Control. Release, 175, 48, 10.1016/j.jconrel.2013.12.006 · DOI
- Dean, 2022, Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study, Lancet Gastroenterol. Hepatol., 7, 943, 10.1016/S2468-1253(22)00167-4 · DOI
- Wong, 2014, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob. Health, 2, e106, 10.1016/S2214-109X(13)70145-1 · DOI
- Ammar, 2020, Age-related macular degeneration therapy: a review, Curr. Opin. Ophthalmol., 31, 215, 10.1097/ICU.0000000000000657 · DOI
- Andreoli, 2007, Anti-vascular endothelial growth factor therapy for ocular neovascular disease, Curr. Opin. Ophthalmol., 18, 502, 10.1097/ICU.0b013e3282f0ca54 · DOI
- Bressler, 2000, Photodynamic therapy with verteporfin (Visudyne), Impact Ophthalmol. Visual Sci., 41
- Woodburn, 2002, Photodynamic Therapy for Choroidal Neovascularization: a review, Retina, 22, 391, 10.1097/00006982-200208000-00001 · DOI
- Phan, 2021, Predictors of visual acuity after treatment of neovascular age-related macular degeneration – current perspectives, OPTH., 15, 3351, 10.2147/OPTH.S205147 · DOI
- Yerramothu, 2018, New therapies of neovascular AMD—beyond anti-VEGFs, Vision, 2, 31, 10.3390/vision2030031 · DOI
- Rosenberg, 2023, Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis, Eye, 37, 6, 10.1038/s41433-022-02020-7 · DOI
- Sugahara, 2009, Tissue-penetrating delivery of compounds and nanoparticles into tumors, Cancer Cell, 16, 510, 10.1016/j.ccr.2009.10.013 · DOI
- Teesalu, 2013, Tumor-penetrating peptides, Front. Oncol., 3, 10.3389/fonc.2013.00216 · DOI
- Lingasamy, 2020, Tumor-penetrating peptide for systemic targeting of tenascin-C, Sci. Rep., 10, 5809, 10.1038/s41598-020-62760-y · DOI
- Lim, 2005, Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal Neovascular membranes, Am J. Ophthalmol., 140, 1044, 10.1016/j.ajo.2005.07.021 · DOI
- Nicolò, 2000, Detection of tenascin-C in surgically excised choroidal neovascular membranes, Clin. Invest., 238, 107
- Kobayashi, 2016, Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin αV, Lab. Investig., 96, 1178, 10.1038/labinvest.2016.99 · DOI
- Ishikawa, 2015, Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy, Invest. Ophthalmol. Vis. Sci., 56, 932, 10.1167/iovs.14-15589 · DOI
- Danen, 2013, Integrin signaling as a Cancer drug target, ISRN Cell Biol., 2013, 1, 10.1155/2013/135164 · DOI
- Friedlander, 1996, Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases, Proc. Natl. Acad. Sci. U. S. A., 93, 9764, 10.1073/pnas.93.18.9764 · DOI
- Ning, 2008, Expression of integrins in human proliferative diabetic retinopathy membranes, Can. J. Ophthalmol., 43, 683, 10.3129/i08-145 · DOI
- Lambert, 2013, Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice, Nat. Protoc., 8, 2197, 10.1038/nprot.2013.135 · DOI
- Fabian-Jessing, 2022, Animal models of choroidal neovascularization: a systematic review, Invest. Ophthalmol. Vis. Sci., 63, 11, 10.1167/iovs.63.9.11 · DOI
- Schmitt, 2019, Intravitreal pharmacokinetics in mice: SPECT/CT imaging and scaling to rabbits and humans, Mol. Pharm., 16, 4399, 10.1021/acs.molpharmaceut.9b00679 · DOI
- Fernández-Robredo, 2017, Neuropilin 1 involvement in choroidal and retinal neovascularisation, PLoS One, 12, 10.1371/journal.pone.0169865 · DOI
- Liu, 2017, Animal models of ocular angiogenesis: from development to pathologies, FASEB J., 31, 4665, 10.1096/fj.201700336R · DOI
- Humphrey, 1997, Retinal GFAP and bFGF expression after multiple argon laser photocoagulation injuries assessed by both immunoreactivity and mRNA levels, Exp. Eye Res., 64, 361, 10.1006/exer.1996.0219 · DOI
- Ghazi-Nouri, 2003, Laser photocoagulation alters the pattern of staining for neurotrophin-4, GFAP, and CD68 in human retina, Br. J. Ophthalmol., 87, 488, 10.1136/bjo.87.4.488 · DOI
- Reinhard, 2017, Tenascins in retinal and optic nerve neurodegeneration, Front. Integr. Neurosci., 11, 30, 10.3389/fnint.2017.00030 · DOI
- Kobayashi, 2016, Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy, Mol. Vis., 22, 436
- Wiemann, 2021, Knock-out of tenascin-C ameliorates ischemia-induced rod-photoreceptor degeneration and retinal dysfunction, Front. Neurosci., 15, 10.3389/fnins.2021.642176 · DOI
- Junnuthula, 2021, Intravitreal polymeric nanocarriers with long ocular retention and targeted delivery to the retina and optic nerve head region, Pharmaceutics, 13, 445, 10.3390/pharmaceutics13040445 · DOI
- Sadeghi, 2022, Imaging, quantitation and kinetic modelling of intravitreal nanomaterials, Int. J. Pharm., 621, 10.1016/j.ijpharm.2022.121800 · DOI
Cited by
Sorted by citations
Sheng, J., Yuan, W., Zhang, M., Chen, Z., Qi, Y., Zhao, Y., & Zhang, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04028-7 · Cited by 35
Metadata
- Authors
- Puranen, J., Korhonen, S., Haugas, M., Lingasamy, P., Teesalu, T., Subrizi, A., Urtti, A., Ruponen, M., & Reinisalo, M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 360
- Pages
- 810-817
- ISSN
- 0168-3659
- Cited by
- 10
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
